Last reviewed · How we verify
Tongjiang granule
At a glance
| Generic name | Tongjiang granule |
|---|---|
| Sponsor | Xiyuan Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome (PHASE1, PHASE2)
- Tongjiang Series Prescription Combined With PPIs Descending Ladder Withdrawal in Treating Nonerosive Reflux Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tongjiang granule CI brief — competitive landscape report
- Tongjiang granule updates RSS · CI watch RSS
- Xiyuan Hospital of China Academy of Chinese Medical Sciences portfolio CI